Groupama Asset Managment Increases Stake in Ionis Pharmaceuticals, Inc. $IONS

Groupama Asset Managment grew its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 7.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 824,540 shares of the company’s stock after acquiring an additional 57,651 shares during the period. Groupama Asset Managment’s holdings in Ionis Pharmaceuticals were worth $61,915,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Capital World Investors boosted its stake in shares of Ionis Pharmaceuticals by 41.2% during the 4th quarter. Capital World Investors now owns 17,961,299 shares of the company’s stock worth $1,420,918,000 after acquiring an additional 5,238,571 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Ionis Pharmaceuticals by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 3,148,849 shares of the company’s stock worth $249,158,000 after purchasing an additional 82,560 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Ionis Pharmaceuticals by 9.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,987,840 shares of the company’s stock worth $236,370,000 after purchasing an additional 258,155 shares in the last quarter. Baker BROS. Advisors LP raised its holdings in Ionis Pharmaceuticals by 216.1% in the 4th quarter. Baker BROS. Advisors LP now owns 1,791,841 shares of the company’s stock worth $141,753,000 after purchasing an additional 1,225,043 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Ionis Pharmaceuticals by 1.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,541,841 shares of the company’s stock worth $121,975,000 after purchasing an additional 21,890 shares during the period. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Insider Activity

In other Ionis Pharmaceuticals news, EVP Holly B. Kordasiewicz sold 362 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $84.30, for a total value of $30,516.60. Following the completion of the transaction, the executive vice president directly owned 22,096 shares in the company, valued at $1,862,692.80. This represents a 1.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP C Frank Bennett sold 5,536 shares of the stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $83.58, for a total transaction of $462,698.88. Following the sale, the executive vice president directly owned 75,018 shares of the company’s stock, valued at approximately $6,270,004.44. This trade represents a 6.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 233,163 shares of company stock valued at $18,316,551 in the last three months. 1.81% of the stock is currently owned by insiders.

Key Ionis Pharmaceuticals News

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Ionis beat Wall Street’s second-quarter revenue and earnings expectations, helped by commercial growth despite difficult year-over-year comparisons. Management also reaffirmed its 2026 outlook, supporting confidence in the company’s operating trajectory. Zacks Q2 earnings report
• Positive Sentiment: Director Michael R. Hayden bought 15,000 shares for approximately $800,700 on July 30 and another 5,000 shares for $258,000 on July 31. The purchases materially increased his ownership and may be viewed as a signal of confidence in Ionis’s valuation and prospects. SEC insider-trading filing
• Neutral Sentiment: Wells Fargo lowered its price target from $100 to $95 while maintaining an “overweight” rating. The reduced target reflects more cautious valuation expectations, but the rating remains bullish. Benzinga analyst report
• Neutral Sentiment: HC Wainwright cut its target from $125 to $115 but retained a “buy” rating, similarly indicating lower near-term valuation expectations while maintaining a positive view of the stock. StreetInsider analyst report
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Ionis investors. Although the announcement does not establish wrongdoing, it adds legal and reputational uncertainty and may weigh on sentiment. Pomerantz investor alert

Ionis Pharmaceuticals Trading Down 2.8%

Shares of IONS stock opened at $51.77 on Friday. The company has a debt-to-equity ratio of 3.07, a quick ratio of 4.09 and a current ratio of 7.89. The stock has a fifty day simple moving average of $69.55 and a two-hundred day simple moving average of $74.57. The firm has a market capitalization of $8.56 billion, a PE ratio of -14.96 and a beta of 0.36. Ionis Pharmaceuticals, Inc. has a 52-week low of $40.03 and a 52-week high of $86.74.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.29. The business had revenue of $246.09 million for the quarter, compared to the consensus estimate of $195.56 million. Ionis Pharmaceuticals had a negative return on equity of 111.08% and a negative net margin of 64.76%.The business’s revenue was up 86.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.93) earnings per share. On average, analysts predict that Ionis Pharmaceuticals, Inc. will post -3.69 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on IONS shares. Canaccord Genuity Group cut their price target on Ionis Pharmaceuticals from $110.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 10th. Jefferies Financial Group lowered their price objective on Ionis Pharmaceuticals from $113.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, July 9th. Raymond James Financial set a $87.00 price objective on Ionis Pharmaceuticals in a research note on Thursday, July 9th. HC Wainwright reduced their target price on shares of Ionis Pharmaceuticals from $125.00 to $115.00 and set a “buy” rating for the company in a report on Thursday. Finally, Morgan Stanley reduced their target price on shares of Ionis Pharmaceuticals from $130.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, July 10th. Eighteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $94.85.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.